• Bristol Myers Squibb is presenting interim Phase 1 Breakfree-2 results for investigational multiple sclerosis therapy zola-cel today at MSToronto 2026.
• Early findings showed potential to control relapses and stabilize disability in patients with highly active relapsing or progressive disease.
• All patients receiving the higher dose remained off disease-modifying therapies at last follow-up, including some followed for more than a year.
• Most adverse events were brief and reversible; one severe neurological event resolved with treatment.
• Following the data cutoff, one patient died from septic pneumonia following high-dose cyclophosphamide treatment for unresolved motor symptoms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202610231030BIZWIRE_USPR_____20261022_BW949204) on October 23, 2026, and is solely responsible for the information contained therein.